neuroendocrine tumors. ESMO

ESMO: Eyeing Novartis and Pfizer, Chi-Med touts neuroendocrine cancer win
Fierce Pharma
Mon, 09/30/19 - 10:38 am
Chi-Med
surufatinib
Pfizer
Sutent
Novartis
Afinitor
Lutathera
neuroendocrine tumors. ESMO